Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Prospectus Supplement No. 13

(to prospectus dated March 22, 2022)

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-261363

Up to 22,223,858 Shares of Common Stock

Up to 6,317,057 Shares of Common Stock Issuable Upon

Exercise of the Warrants

Up to 2,533,333 Private Warrants

This prospectus supplement no. 13 is being filed to update and supplement the prospectus dated March 22, 2022 (the “Prospectus”) related to (1) the issuance by us of up to 6,317,057 shares of our common stock, par value $0.0001 per share (“Common Stock”) that may be issued upon exercise of warrants to purchase Common Stock at an exercise price of $11.50 per share of Common Stock, including the public warrants and the Private Warrants (as defined in the Prospectus); and (2) the offer and sale, from time to time, by the Selling Securityholders (as defined in the Prospectus) identified in the Prospectus, or their permitted transferees, of (a) up to 22,223,858 shares of Common Stock and (b) up to 2,533,333 Private Warrants, with the information contained in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 8, 2022 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report to this prospectus supplement. Any document, exhibit or information contained in the Quarterly Report that has been deemed furnished and not filed in accordance with Securities and Exchange Commission rules shall not be included in this prospectus supplement. This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and any prior amendments or supplements thereto and if there is any inconsistency between the information therein and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our Common Stock is listed on the Capital Market of the Nasdaq Stock Market LLC (“Nasdaq”), under the symbol “DCGO”. On November 9, 2022, the closing price of our Common Stock was $7.34.

Investing in our securities involves a high degree of risks. See the section entitled “Risk Factors” beginning on page 17 of the Prospectus and any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is November 10, 2022.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39618

DocGo Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		85-2515483
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification Number)

35 West 35^th Street, Floor 6
New York, New York		10001
(Address of Principal Executive Offices)		(Zip Code)

(844) 443-6246

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		DCGO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 3, 2022, 102,826,671 shares of Common Stock, par value $0.0001 per share, were issued and outstanding.

Table of Contents

		Page
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements		1
Item 2. Management’s Discussion and Analysis of Financial Condition and Result of Operations		36
Item 3. Quantitative and Qualitative Disclosures About Market Risk		53
Item 4. Controls and Procedures		53

PART II - OTHER INFORMATION

Item 1. Legal Proceedings		54
Item 1A. Risk Factors		54
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		55
Item 3. Defaults Upon Senior Securities		55
Item 4. Mine Safety Disclosures		55
Item 5. Other Information		55
Item 6. Exhibits		56
Signatures		57

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021		2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended September 30, 2022 and 2021		3

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2022 and 2021		4-5

Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021		6-7

Notes to Unaudited Condensed Consolidated Financial Statements		8-35

DocGo Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEET

	September 30,			December 31,
	2022			2021
	Unaudited			Audited
ASSETS

Current assets:
Cash and cash equivalents	$	169,598,749		$	175,537,221
Accounts receivable, net of allowance of $7,376,957 and $7,377,389 as of September 30, 2022 and December 31, 2021, respectively		79,999,764			78,383,614
Prepaid expenses and other current assets		2,394,324			2,111,656

Total current assets		251,992,837			256,032,491

Property and equipment, net		17,577,830			12,733,889
Intangibles, net		20,647,790			10,678,049
Goodwill		34,533,363			8,686,966
Restricted cash		9,753,575			3,568,509
Operating lease right-of-use assets		8,185,547			4,195,682
Finance lease right-of-use assets		9,421,196			9,307,113
Equity method investment		712,718			589,058
Other assets		3,095,354			3,810,895
Total assets	$	355,920,210		$	309,602,652

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	12,153,337		$	15,833,970
Accrued liabilities		38,558,074			35,110,877
Line of credit		1,025,881			25,881
Notes payable, current		680,703			600,449
Due to seller		9,802,238			1,571,419
Contingent consideration		4,000,000			-
Operating lease liability, current		2,059,278			1,461,335
Finance lease liability, current		2,858,968			3,271,990
Total current liabilities		71,138,479			57,875,921

Notes payable, non-current		1,456,105			1,302,839
Operating lease liability, non-current		6,406,246			2,980,946
Finance lease liability, non-current		6,086,521			6,867,420
Warrant liabilities		-			13,518,502
Total liabilities		85,087,351			82,545,628

Commitments and Contingencies

STOCKHOLDERS’ EQUITY:
Common stock ($0.0001 par value; 500,000,000 shares authorized as of September 30, 2022 and December 31,2021; 102,824,878 and 100,133,953 shares issued and outstanding as of September 30, 2022 and December 31,2021, respectively		10,778			10,013
Additional paid-in-capital		301,522,213			283,161,216
Accumulated deficit		(37,036,937	)		(63,556,714	)
Accumulated other comprehensive loss		(276,213	)		(32,501	)
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries		264,219,841			219,582,014
Noncontrolling interests		6,613,018			7,475,010
Total stockholders’ equity		270,832,859			227,057,024
Total liabilities and stockholders’ equity	$	355,920,210		$	309,602,652

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

DocGo Inc. and Subsidiaries

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021

Revenue, net	$	104,319,894		$	85,838,988		$	331,730,750		$	197,394,379
Expenses:
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)		71,254,838			60,025,728			219,418,873			137,080,202
Operating expenses:
General and administrative		22,186,036			19,612,243			70,684,270			47,239,204
Depreciation and amortization		3,014,864			2,019,576			7,253,656			5,514,303
Legal and regulatory		2,200,964			813,204			6,610,223			2,646,573
Technology and development		1,373,146			854,618			3,663,299			1,980,899
Sales, advertising and marketing		90,856			994,401			2,348,917			3,029,182
Total expenses		100,120,704			84,319,770			309,979,238			197,490,363
Income (loss) from operations		4,199,190			1,519,218			21,751,512			(95,984	)

Other income (expenses):
Interest income (expense), net		334,221			(255,711	)		296,891			(500,849	)
Gain/(loss) on remeasurement of warrant liabilities		(1,831,947	)		-			1,137,070			-
Gain on initial equity method investments		93,371			-			99,840			-
Gain on remeasurement of finance leases		-			-			1,388,273			-
Gain from PPP loan forgiveness		-			142,667			-			142,667
Gain/(loss) on disposal of fixed assets		42,667			-			42,667			(27,730	)
Other income		30,900			-			42,288			-
Total other (expense) income		(1,330,788	)		(113,044	)		3,007,029			(385,912	)

Net income (loss) before income tax benefit (expense)		2,868,402			1,406,174			24,758,541			(481,896	)
Income tax expense		(401,916	)		(604,608	)		(1,163,755	)		(613,531	)
Net income (loss)		2,466,486			801,566			23,594,786			(1,095,427	)
Net loss attributable to noncontrolling interests		(687,944	)		(2,705,954	)		(2,924,992	)		(1,278,363	)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries		3,154,430			3,507,520			26,519,778			182,936
Other comprehensive income
Foreign currency translation adjustment		248,283			69,193			252,854			171,846
Total comprehensive gain	$	3,402,713		$	3,576,713		$	26,772,632		$	354,782

Net income per share attributable to DocGo Inc. and Subsidiaries - Basic	$	0.03		$	0.06		$	0.26		$	0.00
Weighted-average shares outstanding - Basic		98,960,538			58,388,866			100,725,697			58,388,866

Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted	$	0.03		$	0.04		$	0.24		$	0.00
Weighted-average shares outstanding - Diluted		107,403,135			83,701,783			109,168,293			83,701,783

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

DocGo Inc. and Subsidiaries

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

	Series A Preferred Stock					Class A Common Stock					Class B Common Stock					Additional Paid-in-			Accumulated			Accumulated Other Comprehensive			Noncontrolling			Total Stockholders’
	Shares			Amount		Shares			Amount		Shares			Amount		Capital			Deficit			Income			Interests			Equity
Balance - December 31, 2020		28,055		$	-		35,497		$	-		55,008		$	-	$	142,346,852		$	(87,300,472	)	$	(48,539	)	$	11,949,200		$	66,947,041
Effect of reverse acquisition		18,099,548			-		22,900,719			-		35,488,938			-		-			-			-			-			-
Conversion of share due to merger recapitalization		(18,099,548	)		-		(22,900,719	)		7,649		(35,488,938	)		-		-			-			-			-			7,649
Effect of reverse acquisition		-			-		76,489,205			7,649		-			-		142,346,852			(87,300,472	)		(48,539	)		11,949,200			66,954,690
Share issued for services		266			-		171,608			17		-			-		-			-			-			-			17
Stock based compensation		-			-		-			-		-			-		391,534			-			-			-			391,534
Noncontrolling interest contribution		-			-		-			-		-			-		-			-			-			333,025			333,025
Foreign currency translation		-			-		-			-		-			-		-			-			7,998			-			7,998
Net loss attributable to Noncontrolling interests		-			-		-			-		-			-		-			-			-			(320,632	)		(320,632	)
Net loss attributable to stockholders of DocGo Inc. and Subsidiaries		-			-		-			-		-			-		-			(1,678,364	)		-			-			(1,678,364	)
Balance - March 31, 2021		28,321		$	-		76,660,813		$	7,666		-		$	-	$	142,738,386		$	(88,978,836	)	$	(40,541	)	$	11,961,593		$	65,688,268
Stock based compensation		-			-		-			-		-			-		370,000			-			-			-			370,000
Foreign currency translation		-			-		-			-		-			-		-			-			94,655			-			94,655
Net income attributable to Noncontrolling interests		-			-		-			-		-			-		-			-			-			1,748,223			1,748,223
Net loss attributable to stockholders of DocGo Inc. and Subsidiaries		-			-		-			-		-			-		-			(1,646,216	)		-			-			(1,646,216	)
Balance - June 30, 2021		28,321			-		76,660,813		$	7,666		-		$	-	$	143,108,386		$	(90,625,052	)	$	54,114		$	13,709,816		$	66,254,930
UK Ltd. Shares purchase		-			-		-			-		-			-		(280,772	)		-			-			(242,945	)		(523,717	)
Stock based compensation		-			-		-			-		-			-		463,046			-			-			-			463,046
Fees associated with equity raise																	(1,398	)											(1,398	)
Foreign currency translation		-			-		-			-		-			-		-			-			69,193			-			69,193
Net income attributable to Noncontrolling interests		-			-		-			-		-			-		-			-			-			(2,705,954	)		(2,705,954	)
Net income attributable to stockholders of Ambulnz, Inc. and Subsidiaries		-			-		-			-		-			-		-			3,507,520			-			-			3,507,520
Balance - September 30, 2021		28,321		$	-		76,660,813		$	7,666		-		$	-	$	143,289,262		$	(87,117,532	)	$	123,307		$	10,760,917		$	67,063,620

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

DocGo Inc. and Subsidiaries

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(CONTINUED)

	Series A Preferred Stock				Class A Common Stock						Class B Common Stock				Additional Paid-in-			Accumulated			Accumulated Other Comprehensive			Noncontrolling			Total Stockholders’
	Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			Income			Interests			Equity
Balance - December 31, 2021		-	$	-		100,133,953		$	10,013			-	$	-	$	283,161,216		$	(63,556,714	)	$	(32,501	)	$	7,475,010		$	227,057,024
Exercise of stock options		-		-		195,152			195			-		-		374,149			-			-			-			374,344
Stock based compensation		-		-		-			-			-		-		1,422,937			-			-			-			1,422,937
Equity cost																(19,570	)											(19,570	)
Noncontrolling interest contribution		-		-		-			-			-		-		-			-			-			2,063,000			2,063,000
Foreign currency translation		-		-		-			-			-		-		-			-			(5,863	)		-			(5,863	)
Net loss attributable to Noncontrolling interests		-		-		-			-			-		-		-			-			-			(1,257,257	)		(1,257,257	)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries		-		-		-			-			-		-		-			10,629,694			-			-			10,629,694
Balance - March 31, 2022		-	$	-		100,329,105		$	10,208			-	$	-	$	284,938,732		$	(52,927,020	)	$	(38,364	)	$	8,280,753		$	240,264,309
Common stock repurchased		-		-		(70,000	)		(70	)		-		-		(497,829	)		-			-			-			(497,899	)
Exercise of stock options		-		-		417,927			418			-		-		778,648			-			-			-			779,066
Stock based compensation		-		-		-			-			-		-		1,999,619			-			-			-			1,999,619
UK Ltd. Restricted Stock		-		-		8,258			8			-		-		82,297			-			-			-			82,305
Net loss attributable to Noncontrolling interests		-		-		-			-			-		-		-			-			-			(979,791	)		(979,791	)
Foreign currency translation		-		-		-			-			-		-		-			-			10,434			-			10,434
Net income attributable to stockholders of DocGo Inc. and Subsidiaries		-		-		-			-			-		-		-			12,735,653			-			-			12,735,653
Balance - June 30, 2022		-	$	-		100,685,290		$	10,564			-	$	-	$	287,301,467		$	(40,191,367	)	$	(27,930	)	$	7,300,962		$	254,393,696
Common stock repurchased		-		-		-			-			-		-		-			-			-			-			-
Exercise of stock options		-		-		378,941			38			-		-		728,465			-			-			-			728,503
Cashless exercise of options		-		-		354,276			35			-		-		(354	)		-			-			-			(319	)
Stock based compensation		-		-		-			-			-		-		1,015,660			-			-			-			1,015,660
UK Ltd. Restricted Stock		-		-		-			-			-		-		95,543			-			-			-			95,543
Share warrants conversion		-		-		1,406,371			141			-		-		12,381,432			-			-			-			12,381,573
Acquisitions		-		-		-			-			-		-		-			-			-			-			-
Net loss attributable to Noncontrolling interests		-		-		-			-			-		-		-			-			-			(687,944	)		(687,944	)
Foreign currency translation		-		-		-			-			-		-		-			-			(248,283	)		-			(248,283	)
Net income attributable to stockholders of DocGo Inc. and Subsidiaries		-		-		-			-			-		-		-			3,154,430			-			-			3,154,430
Balance - September 30, 2022		-	$	-		102,824,878		$	10,778			-	$	-	$	301,522,213		$	(37,036,937	)	$	(276,213	)	$	6,613,018		$	270,832,859

DocGo Inc. and Subsidiaries

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	23,594,786		$	(1,095,427	)
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation of property and equipment		2,592,244			1,697,380
Amortization of intangible assets		2,269,423			1,432,983
Amortization of finance lease right-of-use assets		2,391,989			2,383,940
(Gain) Loss on disposal of assets		(42,667	)		27,730
Gain from PPP loan forgiveness		-			(142,667	)
Gain from equity method investment		(99,840	)		-
Bad debt expense		2,702,979			2,152,470
Stock based compensation		4,616,056			1,224,580
Gain on remeasurement of finance leases		(1,388,273	)		-
Gain on remeasurement of warrant liabilities		(1,137,070	)		-
Changes in operating assets and liabilities:
Accounts receivable		2,894,650			(28,794,602	)
Prepaid expenses and other current assets		(282,668	)		(4,531,411	)
Other assets		882,432			(1,786,407	)
Accounts payable		(3,983,383	)		9,422,628
Accrued liabilities		2,596,887			24,861,804
Net cash provided by operating activities		37,607,545			6,853,001

CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment		(1,994,161	)		(2,824,916	)
Acquisition of intangibles		(1,956,434	)		(1,571,959	)
Acquisition of businesses		(33,843,373	)		(56,496	)
Proceeds from disposal of property and equipment		-			6,000
Net cash used in investing activities		(37,793,968	)		(4,447,371	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit line		1,000,000			8,000,000
Repayments of notes payable		(585,711	)		(374,456	)
Due to seller		(1,007,800	)		-
Noncontrolling interest contributions		2,063,000			333,025
Proceeds from exercise of stock options		1,880,568			-
Common stock repurchased		(497,759	)		-
Equity costs		(19,570	)		-
Payments on obligations under finance lease		(2,146,857	)		(1,830,823	)

Net cash provided by financing activities		685,871			6,127,746

Effect of exchange rate changes on cash and cash equivalents		(252,854	)		171,846

Net increase in cash and restricted cash		246,594			8,705,222
Cash and restricted cash at beginning of period		179,105,730			34,457,273
Cash and restricted cash at end of period	$	179,352,324		$	43,162,495

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

DocGo Inc. and Subsidiaries

CONSOLIDATED STATEMENTS OF CASH FLOWS
(CONTINUED)

	Nine Months Ended September 30,
	2022		2021
Supplemental disclosure of cash and non-cash transactions:

Cash paid for interest	$	102,203	$	39,637

Cash paid for interest on finance lease liabilities	$	434,580	$	381,937

Cash paid for income taxes	$	917,445	$	613,531

Right-of-use assets obtained in exchange for lease liabilities	$	4,094,731	$	3,569,276

Fixed assets acquired in exchange for notes payable	$	819,231	$	271,194

Acquisition of remaining 20% of Ambulnz UK LTD	$	-	$	228,518

Gain from PPP loan forgiveness	$	-	$	142,667

Reconciliation of cash and restricted cash
Cash	$	169,598,749	$	39,550,926

Restricted Cash		9,753,575		3,611,569

Total cash and restricted cash shown in statement of cash flows	$	179,352,324	$	43,162,495

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Organization and Business Operations

The Business

On November 5, 2021 (the “Closing Date”), DocGo Inc., a Delaware corporation (formerly known as Motion Acquisition Corp) (prior to the Closing Date, “Motion” and after the Closing Date, “DocGo”), consummated the previously announced business combination (the “Closing”) pursuant to that certain Agreement and Plan of Merger dated March 8, 2021 (the “Merger Agreement”), by and among Motion Acquisition Corp., a Delaware corporation (“Motion”), Motion Merger Sub Corp., a Delaware corporation and a direct wholly owned subsidiary of Motion (“Merger Sub”), and Ambulnz, Inc., a Delaware corporation (“Ambulnz”). In connection with the Closing, the registrant changed its name from Motion Acquisition Corp. to DocGo Inc.

As contemplated by the Merger Agreement and as described in Motion’s definitive proxy statement/consent solicitation/prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 14, 2021 (the “Prospectus”), Merger Sub was merged with and into Ambulnz, with Ambulnz continuing as the surviving corporation (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). As a result of the Merger, Ambulnz is a wholly-owned subsidiary of DocGo and each share of Series A preferred stock of Ambulnz, no par value (“Ambulnz Preferred Stock”), Class A common stock of Ambulnz, no par value (“Ambulnz Class A Common Stock”), and Class B common stock of Ambulnz, no par value (“Ambulnz Class B Common Stock,” together with Ambulnz Class A Common Stock, “Ambulnz Common Stock”) was cancelled and converted into the right to receive a portion of merger consideration issuable as common stock of DocGo, par value $0.0001 (“Common Stock”), pursuant to the terms and conditions set forth in the Merger Agreement.

In connection with the Business Combination, DocGo raised $158.0 million of net proceeds. This amount was comprised of $43.4 million of cash held in Motion’s trust account from its initial public offering, net of DocGo’s transaction costs and underwriters’ fees of $9.6 million, and $114.6 million of cash in connection with the PIPE Financing. The transaction costs consisted of banking, legal, and other professional fees, which were recorded as a reduction to additional paid-in capital.

The Business

DocGo Inc. and its Subsidiaries (collectively, the “Company”) is a healthcare transportation and mobile health services (“Mobile Health”) company that uses proprietary dispatch and communication technology to provide quality healthcare transportation and healthcare services in major metropolitan cities in the United States (“U.S.”) and the United Kingdom (“U.K.”). Mobile Health performs in-person care directly to patients in the comfort of their homes, workplaces and other non-traditional locations.

Ambulnz, LLC was originally formed in Delaware on June 17, 2015, as a limited liability company. On November 1, 2017, with an effective date of January 1, 2017, Ambulnz converted its legal structure from a limited liability company to a C-corporation and changed its name to Ambulnz, Inc. Ambulnz is the sole owner of Ambulnz Holdings, LLC (“Holdings”) which was formed in the state of Delaware on August 5, 2015, as a limited liability company. Holdings is the owner of multiple operating entities incorporated in various states in the U.S. as well as within England and Wales, U.K.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2021.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

The Consolidated Balance Sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by U.S. GAAP.

The Unaudited Condensed Consolidated Financial Statements include the accounts and operations of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions are eliminated upon consolidation. Noncontrolling interests (“NCI”) on the Unaudited Condensed Consolidated Financial Statements represent a portion of consolidated joint ventures and a variable interest entity in which the Company does not have direct equity ownership. Accounts and transactions between consolidated entities have been eliminated. Certain amounts in the prior years’ consolidated statements of changes in stockholders’ equity and statements of cash flows have been reclassified to conform to the current year presentation.

Pursuant to the Business Combination, the merger between Motion and Ambulnz, Inc. was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Motion was treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Ambulnz, Inc. stock for the net assets of Motion, accompanied by a recapitalization. The net assets of Motion are stated at historical cost, with no goodwill or other intangible assets recorded. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Ambulnz, Inc. The shares and corresponding capital amounts and earnings per share available for common stockholders, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio (645.1452 to 1) established in the Business Combination. Further, Ambulnz, Inc. was determined to be the accounting acquirer in the transaction, as such, the acquisition is considered a business combination under Accounting Standards Codification (“ASC”), Topic 805, Business Combinations, (“ASC 805”) and was accounted for using the acquisition method of accounting.

Principles of Consolidation

The accompanying Unaudited Condensed Consolidated Financial Statements include the accounts of DocGo Inc. and its subsidiaries. All significant intercompany transactions and balances have been eliminated in these Unaudited Condensed Consolidated Financial Statements.

The Company holds a variable interest in MD1 Medical Care P.C. (“MD1”) which contracts with physicians and other health professionals in order to provide services to the Company. MD1 is considered a variable interest entity (“VIE”) since it does not have sufficient equity to finance its activities without additional subordinated financial support. An enterprise having a controlling financial interest in a VIE must consolidate the VIE if it has both power and benefits—that is, it has (1) the power to direct the activities of a VIE that most significantly impacts the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). The Company has the power and rights to control all activities of MD1 and funds and absorbs all losses of the VIE and appropriately consolidates MD1.

Net loss for the VIE was $207,368 and $321,079 as of September 30, 2022 and 2021, respectively. The VIE’s total assets, all of which were current, amounted to $301,503 and $220,081 on September 30, 2022 and 2021, respectively. Total liabilities, all of which were current for the VIE, was $933,977 on September 30, 2022. The VIE’s total stockholders’ deficit was $632,474 and $30,914 on September 30, 2022 and 2021, respectively.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

Foreign Currency

The Company’s functional currency is the U.S. dollar. The functional currency of our foreign operation is the respective local currency. Assets and liabilities of foreign operations denominated in local currencies are translated at the spot rate in effect at the applicable reporting date, except for equity accounts which are translated at historical rates. The Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income are translated at the weighted average rate of exchange during the applicable period. The resulting unrealized cumulative translation adjustment is not material to the financial statements.

Use of Estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to revenue recognition related to the allowance for doubtful accounts, stock based compensation, calculations related to the incremental borrowing rate for the Company’s lease agreements, estimates related to ongoing lease terms, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, reserve for losses within the Company’s insurance deductibles, income taxes, and deferred income tax. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.

Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Concentration of Credit Risk and Off-Balance Sheet Risk

The Company is potentially subject to concentration of credit risk with respect to its cash, cash equivalents and restricted cash, which the Company attempts to minimize by maintaining cash, cash equivalents and restricted cash with institutions of sound financial quality. At times, cash balances may exceed limits federally insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the funds are held. The Company has no financial instruments with off-balance sheet risk of loss.

Major Customers

The Company has one customer that accounted for approximately 33% of sales and 35% of net accounts receivable, and another customer that accounted for 11% of sales and 0.1% of net accounts receivable for the nine month period ended September 30, 2022.

The Company has one customer that accounted for approximately 44% of sales and 42% of net accounts receivable for the nine month period ended September 30, 2021. The Company expects to maintain these relationships with the above-referenced customers.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non- emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Cash and Cash Equivalents

Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less. The Company maintains most of its cash and cash equivalents with financial institutions in the U.S. The accounts at financial institutions in the U.S. are insured by the Federal Deposit Insurance Corporation (“FDIC”) and are in excess of FDIC limits. The Company had cash balances of approximately $433,000 and $913,000 with foreign financial institutions on September 30, 2022 and December 31, 2021, respectively.

Restricted Cash and Insurance Reserves

Cash and cash equivalents subject to contractual restrictions and not readily available are classified as restricted cash in the Condensed Consolidated Balance Sheets. Restricted cash is classified as either a current or non-current asset depending on the restriction period. The Company is required to pledge or otherwise restrict a portion of cash and cash equivalents as collateral for its line of credit, transportation equipment leases and a standby letter of credit as required by its insurance carrier (see Notes 8 and 13).

The Company utilizes a combination of insurance and self-insurance programs, including a wholly-owned captive insurance entity, to provide for the potential liabilities for certain risks, including workers’ compensation, automobile liability, general liability and professional liability. Liabilities associated with the risks that are retained by the Company within its high deductible limits are not discounted and are estimated, in part, by considering claims experience, exposure and severity factors and other actuarial assumptions. The Company has commercial insurance in place for catastrophic claims above its deductible limits.

ARM Insurance, Inc. a Vermont-based wholly-owned captive insurance subsidiary of the Company, charges the operating subsidiaries premiums to insure the retained workers’ compensation, automobile liability, general liability and professional liability exposures. Pursuant to Vermont insurance regulations, ARM Insurance, Inc. maintains certain levels of cash and cash equivalents related to its self-insurance exposures.

The Company also maintains certain cash balances related to its insurance programs, which are held in a self-depleting trust and restricted as to withdrawal or use by the Company other than to pay or settle self-insured claims and costs. These amounts are reflected in “Restricted cash” in the accompanying Condensed Consolidated Balance Sheets.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

Fair Value of Financial Instruments

ASC 820, Fair Value Measurements, provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2022 and December 31, 2021. For certain financial instruments, including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, restricted cash, accounts payable and accrued expenses, and due to seller, the carrying amounts approximate their fair values as it is short term in nature. The notes payable are presented at their carrying value, which based on borrowing rates currently available to the Company for loans with similar terms, approximates its fair values.

Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Future changes in fair value of the contingent financial milestone consideration, as a result of changes in significant inputs such as the discount rate and estimated probabilities of financial milestone achievements, could have a material effect on the statement of operations and balance sheet in the period of the change.

During the three months ended September 30, 2022, the Company recorded $4.0 million of contingent consideration in connection with the Ryan Brothers Atkinson, LLC business acquisition, to be paid based on the completion of certain performance obligations over a 24-month period (see Note 4).

Accounts Receivable

The Company contracts with hospitals, healthcare facilities, businesses, state and local government entities, and insurance providers to transport patients and to provide Mobile Health services at specified rates. Accounts receivable consist of billings for transportation and healthcare services provided to patients. The billings will either be paid or settled on the patient’s behalf by health insurance providers, managed care organizations, treatment facilities, government sponsored programs, businesses, or patients directly. Accounts receivable are net of insurance provider contractual allowances, which are estimated at the time of billing based on contractual terms or other arrangements. Accounts receivable are periodically evaluated for collectability based on past credit history with payors and their current financial condition. Changes in the estimated collectability of accounts receivable are recorded in the results of operations for the period in which the estimate is revised. Accounts receivable deemed uncollectible are offset against the allowance for uncollectible accounts. The Company generally does not require collateral for accounts receivable.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization. When an item is sold or retired, the costs and related accumulated depreciation or amortization are eliminated, and the resulting gain or loss, if any, is recorded in operating expenses in the Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income. The Company provides for depreciation and amortization using the straight-line method over the estimated useful lives of the respective assets. A summary of estimated useful lives is as follows:

Asset Category		Estimated Useful Life
Buildings		39 years
Office equipment and furniture		3 years
Vehicles		2-8 years
Medical equipment		2-5 years
Leasehold improvements		Shorter of useful life of asset or lease term

Expenditures for repairs and maintenance are expensed as incurred. Expenditures that improve an asset or extend its estimated useful life are capitalized.

Software Development Costs

Costs incurred during the preliminary project stage, maintenance costs and routine updates and enhancements of products are expensed as incurred. The Company capitalizes software development costs intended for internal use in accordance with ASC 350-40, Internal-Use Software. Costs incurred in developing the application of its software and costs incurred to upgrade or enhance product functionalities are capitalized when it is probable that the expenses would result in future economic benefits to the Company and the functionalities and enhancements are used for their intended purpose. Capitalized software costs are amortized over its useful life.

Estimated useful life of software development activities are reviewed annually or whenever events or changes in circumstances indicate that intangible assets may be impaired and adjusted as appropriate to reflect upcoming development activities that may include significant upgrades or enhancements to the existing functionality.

Business Combinations

The Company accounts for its business combinations under the provisions of ASC 805-10, Business Combinations (“ASC 805-10”), which requires that the purchase method of accounting be used for all business combinations. Assets acquired and liabilities assumed, including NCI, are recorded at the date of acquisition at their respective fair values. ASC 805-10 also specifies criteria that intangible assets acquired in a business combination must meet to be recognized and reported apart from goodwill.

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date and any changes in fair value after the acquisition date are accounted for as measurement-period adjustments. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. For transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. The Company capitalizes acquisition-related costs and fees associated with asset acquisitions and immediately expenses acquisition-related costs and fees associated with business combinations.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

The estimated fair value of net assets to be acquired, including the allocation of the fair value to identifiable assets and liabilities, is determined using established valuation techniques. Management uses assumptions based on historical knowledge of the business and projected financial information of the target. These assumptions may vary based on future events, perceptions of different market participants and other factors outside the control of management, and such variations may be significant to estimated values.

Impairment of Long-Lived Assets

The Company evaluates the recoverability of the recorded amount of long-lived assets, primarily property and equipment and finite-lived intangible assets, whenever events or changes in circumstance indicate that the recorded amount of an asset may not be fully recoverable. An impairment is assessed when the undiscounted expected future cash flows derived from an asset are less than its carrying amount. If an asset is determined to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. Assets targeted for disposal are reported at the lower of the carrying amount or fair value less cost to sell. For the periods ending September 30, 2022 and December 31, 2021, management determined that there was no impairment loss required to be recognized for the carrying value of long-lived assets.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill represents the excess of the purchase price of an acquired business over the fair value of amounts assigned to assets acquired and liabilities assumed. Goodwill and indefinite-lived intangible assets, consisting primarily of operating licenses, are not amortized, but are evaluated for impairment on an annual basis, or on an interim basis when events or changes in circumstances indicate that the carrying value may not be recoverable. In assessing the recoverability of goodwill and indefinite-lived intangible assets, the Company makes assumptions regarding the estimated future cash flows, including forecasted revenue growth, projected gross margin and the discount rate to determine the fair value of these assets. If these estimates or their related assumptions change in the future, the Company may be required to record impairment charges against these assets in the reporting period in which the impairment is determined.

The Company tests goodwill for impairment at the reporting unit level, which is one level below the operating segment. The Company has the option of performing a qualitative assessment to determine whether further impairment testing is necessary before performing the one-step quantitative assessment. If as a result of the qualitative assessment, it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, a quantitative impairment test will be required. Otherwise, no further testing will be required. If a quantitative impairment test is performed, the Company compares the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. Estimating the fair value of the reporting units requires significant judgment by management. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, goodwill impairment is recognized.

Any excess in carrying value over the estimated fair value is recorded as impairment loss and charged to the results of operations in the period such determination is made. For the periods ended September 30, 2022 and 2021, management determined that there was no impairment loss required to be recognized in the carrying value of goodwill or other intangible assets. The Company selected December 31 as its annual testing date.

Line of Credit

The costs associated with the Company’s line of credit are deferred and recognized over the term of the line of credit as interest expense.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates its financial instruments to determine if such instruments contain features that qualify as embedded derivatives.

Related Party Transactions

The Company defines related parties as affiliates of the Company, entities for which investments are accounted for by the equity method, trusts for the benefit of employees, principal owners (beneficial owners of more than 10% of the voting interest), management, and members of immediate families of principal owners or management, other parties with which the Company may deal with if one party controls or can significantly influence management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Related party transactions are recorded within operating expenses in the Company’s Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income. For details regarding the related party transactions that occurred during the periods ended September 30, 2022 and 2021, refer to Note 15.

Revenue Recognition

On January 1, 2019, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”), as amended.

To determine revenue recognition for contractual arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify each contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when (or as) the relevant performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company provides to the customer.

The Company generates revenues from the provision of (1) ambulance and medical transportation services (“Transportation Services”) and (2) Mobile Health services. The customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations immediately. The Company has utilized the “right to invoice” expedient which allows an entity to recognize revenue in the amount of consideration to which the entity has the right to invoice when the amount that the Company has the right to invoice corresponds directly to the value transferred to the customer. Revenues are recorded net of an estimated contractual allowances for claims subject to contracts with responsible paying entities. The Company estimates contractual allowances at the time of billing based on contractual terms, historical collections, or other arrangements. All transaction prices are fixed and determinable, which includes a fixed base rate, fixed mileage rate and an evaluation of historical collections by each payer.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

Nature of Our Services

Revenue is primarily derived from:

Transportation Services: These services encompass both emergency response and non-emergency ambulance transport services. Net revenue from transportation services is derived from the transportation of patients based on billings to third party payors and healthcare facilities.

ii.

Mobile Health Services: These services include services performed at home and offices, testing and vaccinations, and event services which include on-site healthcare support at sporting events and concerts.

The Company concluded that Transportation Services and any related support activities are a single performance obligation under ASC 606. The transaction price is determined by the fixed rate usage-based fees or fixed fees which are agreed upon in the Company’s executed contracts. For Mobile Health, the performance of the services and any related support activities are a single performance obligation under ASC 606. Mobile Health services are typically billed based on a fixed rate (i.e., time and materials separately or combined) fee structure taking into consideration staff and materials utilized.

As the performance associated with such services is known and quantifiable at the end of a period in which the services occurred (i.e., monthly or quarterly), revenues are typically recognized in the respective period performed. The typical billing cycle for Transportation Services and Mobile Health services is same day to 5 days with payments generally due within 30 days. For large municipal customers in the Mobile Health segment, invoices are generally produced on a monthly basis, in arrears, and are generally due within 30-60 days of when they are submitted to the customer. For Transportation Services, the Company estimates the amount unbilled at month end and recognizes such amounts as revenue, based on available data and customer history. The Company’s Transportation Services and Mobile Health services each represent a single performance obligation. Therefore, allocation is not necessary as the transaction price (fees) for the services provided is standard and explicitly stated in the contractual fee schedule and/or invoice. The Company monitors and evaluates all contracts on a case-by-case basis to determine if multiple performance obligations are present in a contractual arrangement.

For Transportation Services, the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations at the same time. For Transportation Services, where the customer pays fixed rate usage-based fees, the actual usage in the period represents the best measure of progress. Generally, for Mobile Health services, the customer simultaneously receives and consumes the benefits provided by the Company as the performance obligations are fulfilled, therefore the Company satisfies performance obligations at the same time. For certain Mobile Health services that have a fixed fee arrangement, and the services are provided over time, revenue is recognized over time as the services are provided to the customer.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

In the following table, revenue is disaggregated as follows:

Revenue Breakdown	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Primary Geographical Markets
United States	$	101,337,899	$	83,286,509	$	322,706,143	$	190,595,217
United Kingdom		2,981,995		2,552,479		9,024,607		6,799,162
Total revenue	$	104,319,894	$	85,838,988	$	331,730,750	$	197,394,379

Major Segments/Service Lines
Transportation Services	$	27,670,109	$	17,916,162	$	77,657,852	$	65,657,141
Mobile Health		76,649,785		67,922,826		254,072,898		131,737,238
Total revenue	$	104,319,894	$	85,838,988	$	331,730,750	$	197,394,379

Stock Based Compensation

The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. The Company accounts for forfeitures as they occur. All stock-based compensation costs are recorded in operating expenses in the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income.

Earnings per Share

Earnings per share represents the net income attributable to stockholders divided by the weighted-average number of shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting periods. Potential dilutive common stock equivalents consist of the incremental common stock issuable upon exercise of warrants and the incremental shares issuable upon conversion of stock options. In reporting periods in which the Company has a net loss, the effect is considered anti-dilutive and excluded from the diluted earnings per share calculation.

Equity Method Investment

On October 26, 2021, the Company acquired a 50% interest in RND Health Services Inc. (“RND”) for $655,876. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” on the Condensed Consolidated Balance Sheets. Changes in value of RND are recorded in “Gain from equity method investment” on the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

On November 1, 2021, the Company acquired a 20% interest in National Providers Association, LLC (“NPA”) for $30,000. The Company uses the equity method to account for investments in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee but does not exercise control. The Company’s carrying value in the equity method investee is reflected in the caption “Equity method investment” on the Condensed Consolidated Balance Sheets. Changes in value of NPA are recorded in “Loss from equity method investment” on the Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income. The Company’s judgment regarding its level of influence over the equity method investee includes considering key factors, such as ownership interest, representation on the board of directors, and participation in policy-making decisions. Effective December 21, 2021, three members withdrew from NPA resulting in the remaining two members obtaining the remaining ownership percentage. On December 31, 2021 and September 30, 2022, DocGo owned 50% of NPA.

Under the equity method, the Company’s investment is initially measured at cost and subsequently increased or decreased to recognize the Company’s share of income and losses of the investee, capital contributions and distributions and impairment losses. The Company performs a qualitative assessment annually and recognizes an impairment if there are sufficient indicators that the fair value of the investment is less than carrying value.

Leases

The Company categorizes leases at its inception as either operating or finance leases based on the criteria in FASB ASC 842, Leases, (“ASC 842”). The Company adopted ASC 842 on January 1, 2019, using the modified retrospective approach, and has established a Right-of-Use (“ROU”) Asset and a current and non-current lease liability for each lease arrangement identified. The lease liability is recorded at the present value of future lease payments discounted using the discount rate that approximates the Company’s incremental borrowing rate for the lease established at the commencement date, and the ROU asset is measured as the lease liability plus any initial direct costs, less any lease incentives received before commencement. The Company recognizes a single lease cost, so that the remaining cost of the lease is allocated over the remaining lease term on a straight-line basis.

The Company has lease arrangements for vehicles, equipment, and facilities. These leases typically have original terms not exceeding 10 years and, in some cases contain multi-year renewal options, none of which are reasonably certain of exercise. The Company’s lease arrangements may contain both lease and non-lease components. The Company has elected to combine and account for lease and non-lease components as a single lease component. The Company has incorporated residual value obligations in leases for which there is such occurrences. Regarding short-term leases, ASC 842-10-25-2 permits an entity to make a policy election not to apply the recognition requirements of ASC 842 to short-term leases. The Company has elected not to apply the ASC 842 recognition criteria to any leases that qualify as short-term leases.

Income Taxes

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Recently Issued Accounting Standards Not Yet Adopted

None

3. Property and Equipment, net

Property and equipment, net, as of September 30, 2022 and December 31, 2021 are as follows:

	September 30, 2022			December 31, 2021

Office equipment and furniture	$	2,749,874		$	1,977,808
Buildings		527,283			527,284
Land		37,800			37,800
Transportation equipment		18,477,444			13,772,251
Medical equipment		5,764,863			3,949,566
Leasehold improvements		609,226			616,446
		28,166,490			20,881,155
Less: Accumulated depreciation		(10,588,660	)		(8,147,266	)
Property and equipment, net	$	17,577,830		$	12,733,889

The Company recorded depreciation expense of $1,150,806 and $598,188 for the three months ended September 30, 2022 and 2021, respectively.

The Company recorded depreciation expense of $2,592,244 and $1,697,380 for nine months ended September 30, 2022 and 2021, respectively.

4. Acquisition of Businesses

Government Medical Services, LLC

On July 6, 2022, Holdings, acquired 100% of the outstanding shares of common stock of Government Medical Services, LLC (“GMS”), a provider of medical services. The aggregate purchase price consisted of $20.3 million in cash consideration. Holdings also agreed to pay GMS an additional $3.0 million upon GMS meeting certain performance conditions within a year of the Closing Date. Acquisition costs are included in general and administrative expenses and totaled $0 for the three months ended September 30, 2022 and $800,000 for the nine months ended September 30, 2022.

The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the acquirer. The Company’s unaudited condensed consolidated financial statements include the results of operations of GMS from the date of acquisition. The historical results of operations of GMS were not significant to the Company’s unaudited condensed consolidated results of operations for the periods presented. Under the acquisition method of accounting, the aggregate amount of consideration paid by the Company was allocated to GMS’s net tangible assets and intangible assets based on their estimated fair value on the acquisition date. The preliminary purchase price allocation, as set forth in the table below, reflects various preliminary fair value estimates and analysis prepared by the Company. Any change in the fair value of the net assets of GMS will change the amount of the purchase price allocable to goodwill. Final purchase accounting adjustments may differ materially from preliminary purchase price allocation presented here. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible assets acquired, fair value of right to use assets and associated operating lease liabilities assumed, and net working capital adjustments.

Exceptional Medical Transportation, LLC

On July 13, 2022, the Company acquired 100% of the outstanding shares of common stock of Exceptional Medical Transportation, LLC (“Exceptional”) in exchange for $13.7 million consisting of $7.7 million in cash at closing and $6 million payable over a 24 month period. Exceptional is in the business of providing medical transportation services. Acquisition costs are included in general and administrative expenses totaled $0 for the three months ended September 30, 2022 and $0 for the nine months ended September 30, 2022.

The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the acquirer. The Company’s unaudited condensed consolidated financial statements include the results of operations of Exceptional from the date of acquisition. The historical results of operations of Exceptional were not significant to the Company’s unaudited condensed consolidated results of operations for the periods presented. Under the acquisition method of accounting, the aggregate amount of consideration paid by the Company was allocated to Exceptional’s net tangible assets and intangible assets based on their estimated fair value on the acquisition date. The preliminary purchase price allocation, as set forth in the table below, reflects various preliminary fair value estimates and analysis prepared by the Company. Any change in the fair value of the net assets of Exceptional will change the amount of the purchase price allocable to goodwill. Final purchase accounting adjustments may differ materially from preliminary purchase price allocation presented here. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible assets acquired, fair value of right to use assets and associated operating lease liabilities assumed, and net working capital adjustments.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Ryan Brothers Fort Atkinson, LLC

On August 9, 2022, the Company acquired 100% of the outstanding shares of common stock of Ryan Brothers Fort Atkinson, LLC (“RT”) in exchange for $11.4 million consisting of $7.4 million in cash at closing and $4.0 million of estimated contingent consideration to be paid out over 24 months based on performance of certain obligations. RT is in the business of providing medical transportation services. Acquisition costs are included in general and administrative expenses totaled $0 for the three months ended September 30, 2022 and $0 for the nine months ended September 30, 2022.

The acquisition was accounted for under the acquisition method of accounting, with the Company identified as the acquirer. The Company’s unaudited condensed consolidated financial statements include the results of operations of RT from the date of acquisition. The historical results of operations of RT were not significant to the Company’s unaudited condensed consolidated results of operations for the periods presented. Under the acquisition method of accounting, the aggregate amount of consideration paid by the Company was allocated to RT’s net tangible assets and intangible assets based on their estimated fair value on the acquisition date. The preliminary purchase price allocation, as set forth in the table below, reflects various preliminary fair value estimates and analysis prepared by the Company. Any change in the fair value of the net assets of RT will change the amount of the purchase price allocable to goodwill. Final purchase accounting adjustments may differ materially from preliminary purchase price allocation presented here. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the intangible assets acquired, fair value of right to use assets and associated operating lease liabilities assumed, and net working capital adjustments.

The following table presents the preliminary allocation of the assets acquired and liabilities assumed:

	Ryan Brothers		Exceptional Medical Transport		GMS		Total

Consideration:
Cash Consideration	$	7,422,252	$	6,375,000	$	20,338,789	$	34,136,041
Due to Seller		-		6,000,000		-		6,000,000
Contingent Consideration		4,000,000		-		-		4,000,000
Amounts held under an escrow account		-		1,333,333		-		1,333,333
Total consideration		11,422,252		13,708,333		20,338,789		45,469,374

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash	$	620,548	$	299,050	$	1,005,453	$	1,925,051
Accounts receivable		-		-		3,975,160		3,975,160
Other current assets		136,157		-		30,734		166,891
Property, plant and equipment		2,125,134		2,450,900		4,092		4,580,126
Intangible assets		387,550		125,000		9,794,000		10,306,550
Total identifiable assets acquired		3,269,389		2,874,950		14,809,439		20,953,778

Accounts payable		44,911		-		137,239		182,150
Due to Seller		-		299,050		-		299,050
Other current liabilities		286,792		-		562,809		849,601
Total liabilities assumed		331,703		299,050		700,048		1,330,801

Goodwill		8,484,566		11,132,433		6,229,398		25,846,397

Total purchase price	$	11,422,252	$	13,708,333	$	20,338,789	$	45,469,374

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

5. Goodwill

The Company recorded goodwill in connection with its acquisitions. The changes in the carrying value of goodwill for the period ended September 30, 2022 are as noted in the tables below:

	Carrying Value
Balance at December 31, 2021	$	8,686,966
Goodwill acquired during the period		25,846,397
Balance at September 30, 2022		34,533,363

6. Intangibles

Intangible assets consist of the following as of September 30, 2022 and December 31, 2021:

	September 30, 2022
	Estimated Useful Life (Years)	Gross Carrying Amount		Additions		Accumulated Amortization			Net Carrying Amount
Patents	15 years	$	48,668	$	13,655	$	(9,075	)	$	53,248
Computer software	5 years	$	294,147		11,144		(263,192	)	$	42,099
Operating licenses	Indefinite	$	8,375,514		450,200		-		$	8,825,714
Internally developed software	4-5 years	$	6,013,513		1,907,616		(5,778,894	)	$	2,142,235
Material Contracts	Indefinite		-		62,550		-			62,550
Customer Relationship	9 years		-		9,794,000		(272,056	)	$	9,521,944
		$	14,731,842	$	12,239,165	$	(6,323,217	)	$	20,647,790

	December 31, 2021
	Estimated Useful Life (Years)	Gross Carrying Amount		Additions		Accumulated Amortization			Net Carrying Amount
Patents	15 years	$	19,275	$	29,393	$	(6,367	)	$	42,301
Computer software	5 years		132,816		161,331		(219,388	)		74,759
Operating licenses	Indefinite		8,375,514		-		-			8,375,514
Internally developed software	4-5 years		2,146,501		3,867,012		(3,828,038	)		2,185,475
		$	10,674,106	$	4,057,736	$	(4,053,793	)	$	10,678,049

The Company recorded amortization expense of $990,345 and $552,999 for the three months ended September 30, 2022 and 2021, respectively.

The Company recorded amortization expense of $2,269,423 and $1,432,983 for the nine months ended September 30, 2022 and 2021, respectively.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Future amortization expense at September 30, 2022 for the next five years and in the aggregate are as follows:

	Amortization Expense
2022, remaining	$	680,930
2023		2,078,406
2024		1,510,563
2025		1,460,965
2026		1,094,588
Thereafter		4,934,074
Total	$	11,759,526

Amortization expense
As of September 30, 2022			2,269,423
As of September 30, 2021			1,432,983
As of December 31, 2021			1,845,193

7. Accrued Liabilities

Accrued liabilities consist of the following as of September 30, 2022 and December 31, 2021:

	September 30, 2022		December 31, 2021
Accrued bonus	$	496,660	$	7,260,456
Accrued lab fees		1,363,138		4,885,539
Accrued payroll		7,068,616		3,539,301
Medicare advance		-		975,415
FICA/Medicare liability		759,232		739,629
Accrued general expenses		7,393,906		3,497,418
Accrued subcontractors		11,259,341		9,564,833
Accrued fuel and maintenance		310,064		450,842
Accrued workers compensation		5,465,030		2,259,571
Other current liabilities		12,259		736,021
Accrued legal fees		2,447,997		1,143,629
Accrued insurance liabilities		1,840,420		-
Credit card payable		141,411		58,223
Total accrued liabilities	$	38,558,074	$	35,110,877

8. Line of Credit

On December 17, 2021, Ambulnz-FMC North America, LLC (“FMC NA”), entered into a revolving loan and bridge credit and security agreement with a subsidiary of one of its members with a maximum revolving advance amount of $12,000,000. Each Revolving Advance shall bear interest at a per annum rate equal to the Wall Street Journal Prime Rate (6.25% at September 30, 2022), as the same may change from time to time, plus one percent (1.00%), but in no event less than five percent (5.00%) per annum, calculated on the basis of a 360-day year for the actual number of days in the applicable period. The agreement is subject to certain financial covenants such as an unused fee, whereas the Company shall pay to the subsidiary of one of its members an unused fee in the amount of 0.5% of the average daily amount by which the Revolving Commitment Amount ($12 million) exceeds the principal balance of the aggregate outstanding advances. All accrued and unpaid interest and unused fee shall be due and payable on the first anniversary of the date of the agreement (“Revolving Credit Maturity Date”). This loan is secured by all assets of entities owned 100% by DocGo Inc. As of December 31, 2021, the outstanding balance of the line of credit was zero. On January 26, 2022, the Company drew $1,000,000 to fund operations and meet short-term obligations. As of September 30, 2022, the outstanding balance of the line of credit was $1,000,000.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

9. Notes Payable

The Company has various loans with finance companies with monthly installments aggregating $64,855, inclusive of interest ranging from 2.5% through 8%. The notes mature at various times through 2051 and are secured by transportation equipment.

The following table summarizes the Company’s notes payable:

	September 30, 2022		December 31, 2021
Equipment and financing loans payable, between 2.5% and 8% interest and maturing between January 2022 and May 2051	$	2,136,808	$	1,903,288
Loan received pursuant to the Payroll Protection Program Term Note		-		-
Total notes payable		2,136,808		1,903,288
Less: current portion of notes payable	$	680,703	$	600,449
Total non-current portion of notes payable	$	1,456,105	$	1,302,839

Interest expense was $69,804 and $61,324 for the periods ended September 30, 2022 and December 31, 2021, respectively.

Future minimum annual maturities of notes payable as of September 30, 2022 are as follows:

	Notes Payable
2022, remaining		137,959
2023		582,722
2024		446,812
2025		386,785
2026		311,769
Thereafter		270,761
Total maturities	$	2,136,808
Current portion of notes payable		(680,703	)
Long-term portion of notes payable	$	1,456,105

10. Business Segment Information

The Company conducts business as two operating segments, Transportation Services and Mobile Health services. In accordance with ASC 280, Segment Reporting, operating segments are components of an enterprise for which separate financial information is evaluated regularly by the chief operating decision maker, who is the chief executive officer, in deciding how to allocate resources and assessing performance. The Company’s business operates in two operating segments because the Company’s entities have two main revenue streams, and the Company’s chief operating decision maker evaluates the Company’s financial information and resources and assesses the performance of these resources by revenue stream.

The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Transportation Services and Mobile Health services segments based primarily on results of operations.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Operating results for the business segments of the Company are as follows:

	Transportation Services			Mobile Health Services		Total
Three Months Ended September 30, 2022
Revenues	$	27,670,109		$	76,649,785	$	104,319,894

Income (loss) from operations		(4,213,156	)		8,412,346	$	4,199,190

Total assets	$	173,789,449		$	182,130,761	$	355,920,210

Depreciation and amortization expense	$	2,464,694		$	550,170	$	3,014,864

Stock compensation	$	373,641		$	737,562	$	1,111,203

Long-lived assets	$	19,584,744		$	53,174,239	$	72,758,983

Three Months Ended September 30, 2021
Revenues	$	17,916,162			67,922,826	$	85,838,988

Income (loss) from operations		(11,308,739	)		12,827,957		1,519,218

Total assets	$	115,444,782		$	28,634,083	$	144,078,865

Depreciation and amortization expense	$	1,860,088		$	159,488	$	2,019,576

Stock compensation	$	458,346		$	4,700	$	463,046

Long-lived assets	$	25,641,586		$	2,252,650	$	27,894,236

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

	Transportation Services			Mobile Health Services		Total
Nine Months Ended September 30, 2022
Revenues	$	77,657,852		$	254,072,898	$	331,730,750

Income (loss) from operations		(33,035,470	)		54,786,982	$	21,751,512

Total assets	$	173,789,449		$	182,130,761	$	355,920,210

Depreciation and amortization expense	$	6,271,952		$	981,704	$	7,253,656

Stock compensation	$	1,253,450		$	3,280,309	$	4,533,759

Long-lived assets	$	19,584,744		$	53,174,239	$	72,758,983

Nine Months Ended September 30, 2021
Revenues	$	65,657,142			131,737,237	$	197,394,379

Income (loss) from operations		(15,309,680	)		15,213,696		(95,984	)

Total assets	$	115,444,782		$	28,634,083	$	144,078,865

Depreciation and amortization expense	$	5,214,607		$	299,696	$	5,514,303

Stock compensation	$	1,215,180		$	9,400	$	1,224,580

Long-lived assets	$	25,641,586		$	2,252,650	$	27,894,236

Long-lived assets include property, plant and equipment, goodwill and intangible assets.

Geographic Information

Revenues by geographic location are included in Note 2.

11. Equity

Preferred Stock

In November 2021, the Company’s Series A preferred stock was cancelled and converted into the right to receive a portion of merger consideration issuable as common stock of DocGo, par value $0.0001 (the “Common Stock”), pursuant to the terms and conditions set forth in the Merger Agreement. The Company’s Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity reflect the 2020 shares as if the Merger occurred in 2020.

Prior to the reverse merger, on May 23, 2019, the Series A preferred stock was formed, and 40,000 shares were authorized. Each share of Series A preferred stock was convertible into Class A common stock at a conversion price of $3,000 per share, subject to adjustment as defined in the articles of incorporation.

Series A preferred stockholders had voting rights equivalent to the number of common stock shares issuable upon conversion. The Series A preferred stockholders were entitled to a non-cumulative dividend equal to 8% of the original issue price as defined in the agreement when declared by the board of directors.

The holders of the Series A preferred stock had preferential liquidation rights and rank senior to the holders of common stock. If a liquidation were to occur, the holders of the Series A preferred stock would have been paid an amount equal to $3,000 per share, subject to adjustment as defined in the articles of incorporation, plus all accrued and unpaid dividends thereon. After the payment of the Series A preferred stockholders, the common stockholders would have been paid out on a pro-rata basis.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Common Stock

On November 1, 2017, Ambulnz, Inc. converted its legal structure from a limited liability company to a corporation and converted its membership units into shares of common stock at a rate of 1,000 shares per membership unit. The total authorized number of shares of common stock converted was 100,000 shares, comprised of 35,597 shares of Class A common stock and 64,402 shares of Class B common stock.

Prior to the reverse merger, on May 23, 2019, the Ambulnz, Inc amended and restated its articles of incorporation and the total authorized common stock increased to 154,503 shares, comprised of 78,000 shares of Class A common stock and 76,503 shares of Class B common stock. The Class A common stockholders had voting rights equivalent to one vote per share of common stock and the Class B common stockholders have no voting rights. Dividends may be paid to the common stockholders out of funds legally available, when declared by the board of directors.

Share Repurchase Program

On May 24, 2022, the Company was authorized to purchase up to $40 million of the Company’s common stock under a share repurchase program (the “Program”). During the second quarter of 2022, the Company repurchased 70,000 shares of its common stock for $498,000. These shares were subsequently cancelled. There were no shares repurchased during the third quarter of 2022. The Program does not obligate the Company to acquire any specific number of shares and will expire on November 24, 2023. Under the Program, shares may be repurchased using a variety of methods, including privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as part of accelerated share repurchases, block trades and other methods. The timing, manner, price and amount of any common stock repurchases under the Program are determined by the Company in its discretion and depend on a variety of factors, including legal requirements, price and economic and market conditions.

Preacquisition Warrants

On February 15, 2018, the Company issued warrants to purchase 1,367 shares of Class B common stock at a purchase price of $0.01 per share to an investor in conjunction with a capital investment. The warrants had no expiration date. The fair value on the date of issuance was $5,400 per share, for a total fair value of $7,381,800. On May 23, 2019, the warrants were exchanged for warrants to purchase 2,461 shares of Series A preferred stock at a purchase price of $0.01 per share. The exchanged warrants have no expiration date and had a fair value on the date of issuance of $3,000 per share for a total fair value of $7,383,000. These warrants were cashless exercised in November 2021 for 1,587,700 shares of common DocGo Inc. common stock.

On June 5, 2019, the Company issued warrants to purchase 667 shares of Series A preferred stock at a purchase price of $3,000 per share to an investor in conjunction with a capital investment. The warrants would have expired on June 6, 2029. The fair value on the date of issuance was $2,078 per warrant for a total fair value of $1,386,026. These warrants were cashless exercised in November 2021 for 229,807 shares of common DocGo Inc. common stock.

12. Stock Based Compensation

Stock Options

In 2021, the Company established the DocGo Inc. Equity Incentive Plan (the “Plan”), which replaced Ambulnz, Inc’s 2017 Equity Incentive Plan. The Company reserved 16,607,894 shares of common stock for issuance under the Plan. The Company’s stock options generally vest on various terms based on continuous services over periods ranging from three to five years. The stock options are subject to time vesting requirements through 2032 and are nontransferable. Stock options granted have a maximum contractual term of 10 years. On September 30, 2022, approximately 2.5 million employee stock options on a converted basis had vested.

The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Before the Company’s shares of stock were publicly traded, management took the average of several publicly traded companies that were representative of the Company’s size and industry in order to estimate its expected stock volatility. The expected term of the options represented the period of time the instruments are expected to be outstanding. The Company based the risk-free interest rate on the rate payable on the U.S. Treasury securities corresponding to the expected term of the awards at the date of grant. Expected dividend yield was zero based on the fact that the Company had not historically paid and does not intend to pay a dividend in the foreseeable future.

The Company utilized contemporaneous valuations in determining the fair value of its shares at the date of option grants. Prior to the Merger, each valuation utilized both the discounted cash flow and guideline public company methodologies to estimate the fair value of its shares on a non-controlling and marketable basis. The December 31, 2020 valuations also included an approach that took into consideration a pending non-binding letter of intent from Motion Acquisition Corp. The March 11, 2021 valuation report relied solely on the fair value of the Company’s shares implied by the March 8, 2021 Merger Agreement with Motion Acquisition Corp.

A discount for lack of marketability was applied to the non-controlling and marketable fair value estimates determined above. The determination of an appropriate discount for lack of marketability was based on a review of discounts on the sale of restricted shares of publicly traded companies and put-based quantitative methods. Factors that influenced the size of the discount for lack of marketability included (a) the estimated time it would take for a Company stockholder to achieve marketability, and (b) the volatility of the Company’s business.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

The following assumptions were used to compute the fair value of the stock option grants during the period ended September 30, 2022 and 2021:

	Period Ended September 30, 2022
	2022			2021
Risk-free interest rate		.07% - 2.8	%		.15% - .62	%
Expected term (in years)		4			.5 - 2
Volatility		60% - 64	%		65	%
Dividend yield		0	%		0	%

The following table summarizes the Company’s stock option activity under the Plan for the period ended September 30, 2022:

	Options Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance as of, December 31, 2021		8,422,972		$	6.21		8.77	$	24,706,020
Granted/ Vested during the year		2,183,026			5.92		9.07		-
Exercised during the year		(1,637,159	)		2.04		5.47		-
Cancelled during the year		(706,642	)		7.71		8.82		-
Balance as of September 30, 2022		8,262,197			7.04		8.72	$	22,950,815
Options vested and exercisable at September 30, 2022		2,502,717		$	6.11		8.30	$	10,010,617

The aggregate intrinsic value in the above table is calculated as the difference between fair value of the Company’s common stock price and the exercise price of the stock options. The weighted average grant date fair value per share for stock option grants during the periods ended September 30, 2022 and December 31, 2021 was $5.92 and $2.80, respectively. On September 30, 2022 and December 31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $27,812,078 and $20,792,804, respectively, which the Company expects to recognize over a weighted-average period of approximately 3.73 years.

Restricted Stock Units

The fair value of restricted stock units (“RSUs”) is determined on the date of grant. The Company records compensation expense in the Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income on a straight-line basis over the vesting period for RSUs. The vesting period for employees and members of the Board of Directors ranges from one to four years.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Activity under RSUs was as follows:

	RSUs			Weighted- Average Grant Date Fair Value Per RSU
Balance as of, December 31, 2021		50,192		$	9.97
Granted		146,853			7.15
Vested during the year		(16,645	)		9.97
Forfeited		-			-
Balance as of, September 30, 2022		180,400			7.67
Vested and unissued at September 30, 2022		-
Non-vested at September 30, 2022		180,400			7.67

The total grant-date fair value of RSUs granted during the period ended September 30, 2022 was $1,049,999.

For the period ended September 30, 2022, the Company recorded stock-based compensation expense related to RSUs of $177,840.

As of September 30, 2022, the Company had $1,241,163 in unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted-average period of approximately 3.1 years.

13. Leases

Operating Leases

The Company is obligated to make rental payments under non-cancellable operating leases for office, dispatch station space, and transportation equipment, expiring at various dates through 2026. Under the terms of the leases, the Company is also obligated for its proportionate share of real estate taxes, insurance and maintenance costs of the property. The Company is required to hold certain funds in restricted cash and cash equivalents accounts under some of these agreements.

Certain leases for property and transportation equipment contain options to purchase, extend or terminate the lease. Determining the lease term and amount of lease payments to include in the calculation of the right-of-use (ROU) asset and lease obligations for leases containing options requires the use of judgment to determine whether the exercise of an option is reasonably certain and whether the optional period and payments should be included in the calculation of the associated ROU asset and lease obligation. In making such judgment, the Company considers all relevant economic factors that would require whether to exercise or not exercise the option.

The Company’s lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived imputed rates, which were used to discount its real estate lease liabilities. The Company used estimated borrowing rates of 6% on January 1, 2019, for all leases that commenced prior to that date, for office spaces and transportation equipment.

DocGo Inc. and Subsidiaries

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

Lease Costs

The table below comprise lease expenses for the periods ended September 30, 2022 and 2021:

	Three Months Ended				Nine Months Ended
Components of total lease cost:	September 30, 2022		September 30, 2021		September 30, 2022		September 30, 2021

Operating lease expense	$	626,188	$	508,128	$	1,517,541	$	1,446,067
Short-term lease expense		334,619	$	62,653		863,316		256,448
Total lease cost	$	960,807	$	570,781	$	2,380,857	$	1,702,515

Lease Position as of September 30, 2022

Right-of-use lease assets and lease liabilities for the Company’s operating leases were recorded in the Condensed Consolidated Balance Sheets as follows:

	September 30, 2022		December 31, 2021
Assets
Lease right-of-use assets	$	8,185,547	$	4,195,682
Total lease assets	$	8,185,547	$	4,195,682

Liabilities
Current liabilities:
Lease liability - current portion	$	2,059,278	$	1,461,335
Noncurrent liabilities:
Lease liability, net of current portion

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

DCGO DocGo Inc